Tags

Type your tag names separated by a space and hit enter

Local low dose curcumin treatment improves functional recovery and remyelination in a rat model of sciatic nerve crush through inhibition of oxidative stress.
Neuropharmacology 2018; 139:98-116N

Abstract

Traumatic injuries to peripheral nerves are frequent, however, specific pharmacological treatments are currently lacking. Curcumin has antioxidant, anti-inflammatory and neuroprotective properties but high oral doses are required for therapeutic use, particularly due to its low bioavailability. The aim of the present study was to investigate the effects of local and continuous treatment using low curcumin doses on functional recovery and nerve regeneration after rat sciatic nerve crush (SNC). Curcumin was administered by osmotic pumps with a catheter delivering the drug at the injury site (0.2 mg/day for 4 weeks). Functionally, early improvements in mechanical sensitivity, finger spacing of the injured paw, skilful walking and grip strength were observed in curcumin-treated animals. The curcumin treatment increased expression of compact myelin proteins (MPZ and PMP22), myelin sheath thickness and, correspondingly, increased motor and sensitive nerve conduction velocity. Microscopic analysis of gastrocnemius muscle indicated a curcumin-induced decrease in neurogenic lesions. Curcumin treatment reduced the production of reactive oxygen species (ROS) (which were notably produced by macrophages), lipid peroxidation and increased expression of transcription factor Nrf2. In silico analyses indicated that curcumin combines all the characteristics required to be an efficient lipid peroxidation inhibitor at the heart of biological membranes, hence protecting their degradation due to ROS. This antioxidant capacity is likely to contribute to the beneficial effects of curcumin after SNC injury. These results demonstrate that, when administrated locally, low doses of curcumin represent a promising therapy for peripheral nerve regeneration.

Authors+Show Affiliations

EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France.UMR INSERM 1248 IPPRITT, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; RCPTM, Department of Physical Chemistry, Faculty of Sciences, Palacký University, Olomouc, Czech Republic.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; Reference Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; Department of Biochemistry, University Hospital of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; Department of Biochemistry, University Hospital of Limoges, Limoges, France.UMR INSERM 1094 NET, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; Department of Biochemistry, University Hospital of Limoges, Limoges, France.UMR INSERM 1248 IPPRITT, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France; RCPTM, Department of Physical Chemistry, Faculty of Sciences, Palacký University, Olomouc, Czech Republic.Reference Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France.EA6309 Myelin Maintenance and Peripheral Neuropathies, Faculties of Medicine and Pharmacy, University of Limoges, Limoges, France. Electronic address: fabrice.billet@unilim.fr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30018000

Citation

Caillaud, Martial, et al. "Local Low Dose Curcumin Treatment Improves Functional Recovery and Remyelination in a Rat Model of Sciatic Nerve Crush Through Inhibition of Oxidative Stress." Neuropharmacology, vol. 139, 2018, pp. 98-116.
Caillaud M, Chantemargue B, Richard L, et al. Local low dose curcumin treatment improves functional recovery and remyelination in a rat model of sciatic nerve crush through inhibition of oxidative stress. Neuropharmacology. 2018;139:98-116.
Caillaud, M., Chantemargue, B., Richard, L., Vignaud, L., Favreau, F., Faye, P. A., ... Billet, F. (2018). Local low dose curcumin treatment improves functional recovery and remyelination in a rat model of sciatic nerve crush through inhibition of oxidative stress. Neuropharmacology, 139, pp. 98-116. doi:10.1016/j.neuropharm.2018.07.001.
Caillaud M, et al. Local Low Dose Curcumin Treatment Improves Functional Recovery and Remyelination in a Rat Model of Sciatic Nerve Crush Through Inhibition of Oxidative Stress. Neuropharmacology. 2018 09 1;139:98-116. PubMed PMID: 30018000.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Local low dose curcumin treatment improves functional recovery and remyelination in a rat model of sciatic nerve crush through inhibition of oxidative stress. AU - Caillaud,Martial, AU - Chantemargue,Benjamin, AU - Richard,Laurence, AU - Vignaud,Laetitia, AU - Favreau,Frédéric, AU - Faye,Pierre-Antoine, AU - Vignoles,Philippe, AU - Sturtz,Franck, AU - Trouillas,Patrick, AU - Vallat,Jean-Michel, AU - Desmoulière,Alexis, AU - Billet,Fabrice, Y1 - 2018/07/03/ PY - 2018/02/22/received PY - 2018/05/16/revised PY - 2018/07/02/accepted PY - 2018/7/19/pubmed PY - 2019/3/21/medline PY - 2018/7/19/entrez KW - Curcumin KW - Myelin KW - Oxidative stress KW - Sciatic nerve crush SP - 98 EP - 116 JF - Neuropharmacology JO - Neuropharmacology VL - 139 N2 - Traumatic injuries to peripheral nerves are frequent, however, specific pharmacological treatments are currently lacking. Curcumin has antioxidant, anti-inflammatory and neuroprotective properties but high oral doses are required for therapeutic use, particularly due to its low bioavailability. The aim of the present study was to investigate the effects of local and continuous treatment using low curcumin doses on functional recovery and nerve regeneration after rat sciatic nerve crush (SNC). Curcumin was administered by osmotic pumps with a catheter delivering the drug at the injury site (0.2 mg/day for 4 weeks). Functionally, early improvements in mechanical sensitivity, finger spacing of the injured paw, skilful walking and grip strength were observed in curcumin-treated animals. The curcumin treatment increased expression of compact myelin proteins (MPZ and PMP22), myelin sheath thickness and, correspondingly, increased motor and sensitive nerve conduction velocity. Microscopic analysis of gastrocnemius muscle indicated a curcumin-induced decrease in neurogenic lesions. Curcumin treatment reduced the production of reactive oxygen species (ROS) (which were notably produced by macrophages), lipid peroxidation and increased expression of transcription factor Nrf2. In silico analyses indicated that curcumin combines all the characteristics required to be an efficient lipid peroxidation inhibitor at the heart of biological membranes, hence protecting their degradation due to ROS. This antioxidant capacity is likely to contribute to the beneficial effects of curcumin after SNC injury. These results demonstrate that, when administrated locally, low doses of curcumin represent a promising therapy for peripheral nerve regeneration. SN - 1873-7064 UR - https://www.unboundmedicine.com/medline/citation/30018000/Local_low_dose_curcumin_treatment_improves_functional_recovery_and_remyelination_in_a_rat_model_of_sciatic_nerve_crush_through_inhibition_of_oxidative_stress_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0028-3908(18)30356-3 DB - PRIME DP - Unbound Medicine ER -